Skip to main content

Advertisement

Log in

CASE REPORT: Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCES

  1. Holmes B, Heel RC, Brogden RN, Speight TM, Avery GS: Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 27:301–327, 1984

    Google Scholar 

  2. Dourakis SP, Tzemanakis E, Sinani C, Kafiri G, Hadziyannis SJ: Gliclazide-induced hepatitis. Eur J Gastroenterol Hepatol 12:119–121, 2000

    Google Scholar 

  3. Zimmerman HJ: Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, Lippincott Williams and Wilkins, 1999

    Google Scholar 

  4. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE: Glyburide-induced hepatitis. Ann Intern Med 106:837–839, 1987

    Google Scholar 

  5. Wongpaitoon V, Mills PR, Russell RI, Patrick RS: Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. Postgrad Med J 57:244–246, 1981

    Google Scholar 

  6. Tholakanahalli VN, Potti A, Heyworth MF: Glibenclamideinduced cholestasis. West J Med 168:274–277, 1998

    Google Scholar 

  7. Clarke BF, Campbell IW, Ewing DJ, Beveridge GW, Mac-Donald MK: Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes 23:739–742, 1974

    Google Scholar 

  8. Tzanakis N, Bouros D, Siafakas N: Eosinophilic pleural effusion due to gliclazide. Respir Med 94:94, 2000

    Google Scholar 

  9. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M, et al: International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938, 1999

    Google Scholar 

  10. Poonawala A, Nair SP, Thuluvath PJ: Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case–control study. Hepatology 32:689–692, 2000

    Google Scholar 

  11. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying liver disease. Hepatology 29:664–669, 1999

    Google Scholar 

  12. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067–1075, 2000

    Google Scholar 

  13. Desfaits AC, Serri O, Renier G: Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factoralpha production in NIDDM patients after gliclazide treatment. Diabetes Care 2:487–493, 1998

    Google Scholar 

  14. Coyle WJ, Delaney N, Yoshihashi A, Lawson P: Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology. Gastroenterology 116:A1198, 1999 (abstract)

    Google Scholar 

  15. King PD, Blitzer BL: Drug-induced cholestasis: pathogenesis and clinical features. Semin Liver Dis 10:316–321, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chitturi, S., Le, V., Kench, J. et al. CASE REPORT: Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Dig Dis Sci 47, 1107–1110 (2002). https://doi.org/10.1023/A:1015002526879

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015002526879

Navigation